Pfizer Inc. $PFE Shares Acquired by Ritholtz Wealth Management

Ritholtz Wealth Management lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 71.8% during the second quarter, Holdings Channel reports. The firm owned 89,008 shares of the biopharmaceutical company’s stock after acquiring an additional 37,209 shares during the quarter. Ritholtz Wealth Management’s holdings in Pfizer were worth $2,158,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer during the first quarter worth about $27,000. North Capital Inc. purchased a new position in shares of Pfizer during the first quarter worth about $28,000. Bayforest Capital Ltd purchased a new stake in Pfizer during the 1st quarter valued at approximately $28,000. Horizon Financial Services LLC acquired a new stake in Pfizer during the 1st quarter worth approximately $35,000. Finally, WPG Advisers LLC acquired a new stake in Pfizer during the 1st quarter worth approximately $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Bank of America increased their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Morgan Stanley decreased their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday, October 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Finally, Citigroup increased their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $28.13.

Pfizer Price Performance

Shares of PFE opened at $24.22 on Friday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $29.53. The stock’s 50 day moving average is $24.89 and its two-hundred day moving average is $24.12. The firm has a market capitalization of $137.70 billion, a PE ratio of 12.88, a P/E/G ratio of 0.81 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the previous year, the company earned $0.60 EPS. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. Pfizer’s payout ratio is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.